A glove manufacturer in Malaysia that hasn't been covered by analysts is VIP Gloves.

It is listed on ASX and had a recent market cap of just A$54 million (share price: 7.1 cents).

With a surge in demand for its nitrile gloves during the pandemic, VIP Gloves’ EBITDA (earnings before interest, taxes, depreciation and amortisation) rocketed 340% q-o-q to A$4.5m in 3Q of this calendar year, from A$1m in 2Q.

The current 4Q calendar year 2020 is expected to deliver higher EBITDA as selling prices have gone higher.

On 30 Nov 2020, the company said that its order book was full till end-2021 and its factories were working 24/7.

Two corporate events this month (Dec) caught some market attention:
• The company announced a dividend policy on 8 Dec. The payout ratio would be 20-40% of annual earnings, and dividends are payable semi-annually.

• Insiders have been buying the stock in recent days (Dec) as the company massively expands its manufacturing capacity.

Insider

Date
(2020)

No. of shares bought

Cost / share 
(Aussie)

Latest shareholding*

Wee Min Chen
(exec director)

16 Dec

1,740,000

7.7 cts

48,760,948

11 Dec

870,000

7.5 cts

Peter Yee Ming Ng
(independent director)

15 Dec

48,600

7.2 cts

48,600

Chee Cheong Low
(independent director)

14-15 Dec

80,000

7.5 cts

260,000

Source: https://www2.asx.com.au/markets/company/VIP

See also: 

• VIP Gloves capitalises on soaring demand for PPE equipment



Meanwhile, here are excerpts from CGS-CIMB report on the Malaysian glove scene, featuring the better-known Singapore-listed Riverstone Holdings and UG Healthcare.

Analyst: ONG Khang Chuen, CFA

Gloves – Neutral (Top pick: UG Healthcare) 

UG Healthcare products

 Recent vaccine newsflow has been a dampener to glove makers’ share price, as concerns arise that ASP could see an earlier/steeper decline with the stronger-than-expected effectiveness of Covid-19 vaccines (Pfizer: 95%; Moderna: 95%).

 However, we remain positive on the fundamentals and expect FY21F to be another year of record profits for glove makers.

We also expect ASPs to remain on an uptrend in coming months and stay high in CY21F even with the widespread availability of Covid-19 vaccines.

 Currently, UGHC and RSTON are trading at 4.7x and 9.4x CY22F, respectively, which we think more than priced in earnings normalisation post-Covid-19.

We see positive share price momentum for glove stocks in 1H21F as investors return their focus to near-term fundamentals (post the near-term vaccine euphoria).

UGHC is our preferred pick in the sector given its relatively cheaper valuation and our expectations of higher normalised profits, backed by a 59% yoy manufacturing capacity expansion in CY21F.


All eyes on ASP

 With the recent positive newsflow on vaccine development, all eyes are on how long the elevated glove ASPs can sustain and how ASPs will stabilise post-Covid-19.

We expect ASPs to remain on a firm uptrend in 1Q21F, with the recent resurgence in Covid-19 cases boosting glove demand, while supply remains weak given the disruption from Top Glove’s production halt.

We understand that end-users remain insensitive to pricing and are in fact willing to pay a premium to secure stable supply.

MARGMA notes that the glove industry’s current contractual glove ASPs are about US$70-80 per thousand pcs, some 200% higher than pre-Covid-19 levels (c.US$25).

 Without demand or supply shock in sight, we expect ASPs to stabilise on a gradual basis, in tandem with better demand-supply dynamics starting 2H20F.

MARGMA estimates that ASPs could still remain at c.50-60% above pre-Covid-19 levels by 2023 (c.US$35 per thousand pcs).

We have already factored in more conservative assumptions in our model — we estimate ASP to decline 3% monthly beginning Apr 2021, which brings our ASP assumptions to c.US$35 by end-2022F, about 1 year earlier than MARGMA’s expectations.

 With this, we see fundamentals remaining strong in CY21F, with glove makers on track to another year of record profit.

We forecast UGHC to see net profit growth of 7.7x to S$103m in FY21F, while RSTON can also see net profit growth of 88% yoy to RM1.1bn in FY21F.


Full report here. 

You may also be interested in:


You have no rights to post comments

Counter NameLastChange
AEM Holdings2.740-0.040
Avi-Tech Electronics0.2650.010
Best World1.780-0.030
Broadway Ind0.0870.003
China Sunsine0.380-0.010
ComfortDelGro1.4100.020
Delfi Limited1.040-0.010
Food Empire1.410-0.040
Fortress Minerals0.250-0.010
Geo Energy Res0.410-0.005
GSS Energy0.029-
Hong Leong Finance2.5600.020
Hongkong Land (USD)3.3300.070
InnoTek0.425-
ISDN Holdings0.345-
ISOTeam0.034-0.002
IX Biopharma0.039-0.004
Jiutian Chemical0.026-
KSH Holdings0.2450.005
Leader Env0.053-
Medtecs Intl0.139-0.002
Nordic Group0.350-
Oxley Holdings0.092-0.001
REX International0.123-0.004
Riverstone0.750-0.005
Sinostar PEC0.140-
Southern Alliance Mining0.585-
Straco Corp.0.515-
Sunpower Group0.210-
The Trendlines0.085-0.001
Totm Technologies0.025-0.002
Uni-Asia Group0.875-0.025
Wilmar Intl3.2600.020
Yangzijiang Shipbldg1.670-0.020
 

We have 752 guests and no members online

rss_2 NextInsight - Latest News